Arca
Skip to content
Tools
Tools

IL6: Interleukin-6

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Cytokine with a wide variety of biological functions in immunity, tissue regeneration, and metabolism.

  • Drugs that act on it: 8
  • Approved: 1
  • In phases 1 to 3: 7
  • Sponsors: 6

Who Is On It, and How Far Along

Every drug ChEMBL records acting on IL6, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody
  • Other

Approved1

  • Siltuximab

Phase 34

  • Clazakizumab
  • Olokizumab
  • Ziltivekimab
  • Sirukumab

Phase 22

  • Pacibekitug
  • Elsilimomab

Phase 11

  • Mra 003 us

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

Modalities

Drugs on this target by ChEMBL molecule type.

  • Antibody788%
  • Other113%

The Landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 7 of 8 act as: Interleukin-6 inhibitor; the rest name their own mechanism.
SiltuximabApprovedRecordati Rare DiseasesAntibodyAntagonistInterleukin-6 antagonist11—
ClazakizumabPhase 3CSLAntibodyInhibitor—4—
OlokizumabPhase 3R-Pharm International, LLCAntibodyInhibitor—4—
ZiltivekimabPhase 3Novo NordiskAntibodyInhibitor—4—
SirukumabPhase 3Johnson & JohnsonAntibodyInhibitor—0—
PacibekitugPhase 2Novartis PharmaceuticalsAntibodyInhibitor—1—
ElsilimomabPhase 2—AntibodyInhibitor—0—
Mra 003 usPhase 1—OtherInhibitor—0—

Open Trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 21 in all, from ClinicalTrials.gov.
A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial InfarctionPacibekitugPhase 3Not yet recruitingNovartis Pharmaceuticals2026-11-16
A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)SiltuximabPhase 3Not yet recruitingMerck Sharp & Dohme LLC2026-11-02
A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001)SiltuximabPhase 1Not yet recruitingMerck Sharp & Dohme LLC2026-10-13
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular EventClazakizumabPhase 2RecruitingEli Lilly and Company2026-08-25
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)SiltuximabPhase 2RecruitingMerck Sharp & Dohme LLC2026-07-16
Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE)OlokizumabPhase 3Active, not recruitingR-Pharm International, LLC2026-06-26
Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's DiseaseOlokizumabPhase 3Not yet recruitingR-Pharm International, LLC2026-06-04
A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)ClazakizumabPhase 1RecruitingCSL Behring2026-06-02
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)SiltuximabPhase 2 / Phase 3RecruitingMerck Sharp & Dohme LLC2026-05-06
Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic ArthritisOlokizumabPhase 2RecruitingR-Pharm International, LLC2026-04-08
A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart AttackZiltivekimabPhase 3RecruitingNovo Nordisk A/S2025-12-24
Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial InfarctionZiltivekimabPhase 3RecruitingECRI bv2025-12-11
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple MyelomaSiltuximabPhase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China2025-08-06
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung TransplantationSiltuximabPhase 1RecruitingWashington University School of Medicine2025-05-25
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell TransplantSiltuximabPhase 2RecruitingMemorial Sloan Kettering Cancer Center2024-11-08
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES TrialSiltuximabPhase 2RecruitingYuanquan Yang2024-06-24
Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung DiseasesOlokizumabPhase 2 / Phase 3RecruitingR-Pharm International, LLC2024-06-04
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationZiltivekimabPhase 3Active, not recruitingNovo Nordisk A/S2024-01-10
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart AttackZiltivekimabPhase 3Active, not recruitingNovo Nordisk A/S2023-11-07
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)ClazakizumabPhase 2 / Phase 3RecruitingCSL Behring2022-08-03
Clazakizumab vs. Placebo - COVID-19 InfectionClazakizumabPhase 2RecruitingThe Methodist Hospital Research Institute2020-07-31

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Asthma
0.58
Aortic stenosis
0.56
Immune system disorder
0.51
Aortic valve calcification
0.49
Giant Lymph Node Hyperplasia
0.48
Kaposi sarcoma, susceptibility to
0.46
Hair color
0.46
Aortic valve disorder
0.43

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1795129, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P05231, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.